Roanna Ruiz
Stock Analyst at Leerink Partners
(0.62)
# 3,752
Out of 4,711 analysts
57
Total ratings
26.47%
Success rate
-21.7%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $3.65 | +256.16% | 3 | Oct 25, 2024 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $21 → $25 | $11.18 | +123.61% | 3 | Sep 20, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $4.82 | +190.46% | 1 | Apr 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $359.58 | -8.23% | 1 | Feb 5, 2024 | |
| CYTK Cytokinetics | Initiates: Outperform | $58 | $48.87 | +18.68% | 1 | Aug 15, 2023 | |
| CORT Corcept Therapeutics | Initiates: Market Perform | $25 | $51.40 | -51.36% | 1 | Apr 11, 2023 | |
| ENTA Enanta Pharmaceuticals | Reiterates: Market Perform | $49 | $6.28 | +680.25% | 10 | Feb 9, 2023 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $6 → $5 | $3.49 | +43.27% | 4 | Jan 27, 2023 | |
| VIR Vir Biotechnology | Maintains: Outperform | $45 → $43 | $7.34 | +485.83% | 3 | Jan 27, 2023 | |
| SCPH scPharmaceuticals | Maintains: Outperform | $12 → $13 | $3.39 | +283.48% | 7 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $3.19 | +88.09% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $25.50 | -25.49% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $89.29 | +34.40% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $39.84 | +25.50% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3 → $2 | $0.46 | +334.78% | 6 | Oct 19, 2022 |
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $3.65
Upside: +256.16%
ARS Pharmaceuticals
Sep 20, 2024
Maintains: Outperform
Price Target: $21 → $25
Current: $11.18
Upside: +123.61%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $4.82
Upside: +190.46%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $359.58
Upside: -8.23%
Cytokinetics
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $48.87
Upside: +18.68%
Corcept Therapeutics
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $51.40
Upside: -51.36%
Enanta Pharmaceuticals
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $6.28
Upside: +680.25%
Xeris Biopharma Holdings
Jan 27, 2023
Maintains: Outperform
Price Target: $6 → $5
Current: $3.49
Upside: +43.27%
Vir Biotechnology
Jan 27, 2023
Maintains: Outperform
Price Target: $45 → $43
Current: $7.34
Upside: +485.83%
scPharmaceuticals
Jan 27, 2023
Maintains: Outperform
Price Target: $12 → $13
Current: $3.39
Upside: +283.48%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $3.19
Upside: +88.09%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $25.50
Upside: -25.49%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $89.29
Upside: +34.40%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $39.84
Upside: +25.50%
Oct 19, 2022
Maintains: Market Perform
Price Target: $3 → $2
Current: $0.46
Upside: +334.78%